newsfilter
← Latest News
PR Newswire·

Arcellx Announces Partial Clinical Hold Lifted on iMMagine-1 Phase 2 Clinical Program and Reports Second Quarter Financial Results

-- Company expects to present preliminary data from iMMagine-1 study in 2H'24 -- REDWOOD CITY, Calif., Aug. 14, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy